📁Pharma Team / Shared drive
18 documents across 5 categories
Competitive intel
4 docsDOC
ASCO 2026 Readout — Competitive Implications for Zenvara
Competitor X (BMS CheckMate-X) Ph3 missed primary PFS endpoint (HR 0.91, p=0.18). Reduces near-term 2L threat.
2w ago·Competitive Intel Lead
DOC
KOL Advisory Board — Apr 2026 Synthesis
Eight KOLs across US/EU. Consensus: sequencing question post-progression remains unresolved; demand for head-to-head data is loudest signal.
4w ago·Medical Affairs Director
DOC
Competitor Monitoring Tracker — Zenvara Class
Six assets tracked across Phase 2/3. CheckMate-X failed (May 14); AbbVie pipeline asset entered Ph3 enrollment 2026-04-18.
2w ago·Competitive Intel Analyst
DOC
2026 Congress Calendar & Coverage Plan
Priority: ASCO, ESMO, AHA, ACR. 14 abstracts submitted; symposium slots confirmed at ESMO and ACR.
Apr 11, 2026·Medical Communications